Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of CGB-500 Topical Ointment With 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial

NCT06810050 is registered in ClinicalTrials.gov with CAGE Bio Inc. as lead sponsor.

NCT NCT06810050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of CGB-500 Topical Ointment With 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial
Lead sponsor
CAGE Bio Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2024
Completion date
October 30, 2025
Enrollment
180 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)